OncoMatch/Clinical Trials/NCT07781358
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Is NCT07781358 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Becotatug Vedotin and PD-1 / PD-L1 monoclonal antibody for nasopharyngeal carcinoma (npc).
Treatment: Becotatug Vedotin · PD-1 / PD-L1 monoclonal antibody — This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug vedotin combined with a PD-1 inhibitor. Following treatment, imaging assessment and surgical evaluation will be performed. Subjects deemed operable will undergo endoscopic nasal surgery, after which the MDT (multidisciplinary team) will discuss and determine a maintenance treatment plan. For subjects who are not eligible for surgery, the MDT will decide on either maintenance therapy or a switch to an alternative treatment regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate containing MMAE
Prior treatment with an ADC drug containing MMAE as the payload.
Lab requirements
Blood counts
adequate organ function for drugs and surgery
Kidney function
adequate organ function for drugs and surgery
Liver function
adequate organ function for drugs and surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07781358 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate containing MMAE disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages